Nexplanon 68 MG implants
Ended Awarded Last action
- Contract number
- SPE2DR26FRRN8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,086
Award facts
- Contract value 100% obligated
- $15,086.34 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $15,086.34 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of 68 mg Nexplanon implants. The delivery order was issued on January 27, 2026, with an ultimate completion date of February 18, 2026, and carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition vehicle established to streamline pharmaceutical procurement for Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its small business status to compete effectively in unrestricted procurement. The company's PPV-G GEN V prime vendor contract, valued at $499,999,999 with a completion date of December 31, 2036, authorizes the Defense Logistics Agency to issue delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables to support military healthcare operations globally. This particular delivery order for Nexplanon implants—a subdermal contraceptive device—exemplifies the specialized pharmaceutical and medical product categories covered under the broader prime vendor agreement.
Quick answers
Who was awarded contract SPE2DR26FRRN8?
SPE2DR26FRRN8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FRRN8 worth?
The government has obligated $15,086 on SPE2DR26FRRN8.
Is contract SPE2DR26FRRN8 an order under another contract?
Yes. SPE2DR26FRRN8 is a delivery order under SPE2DR25D9238, an indefinite delivery contract.
Was contract SPE2DR26FRRN8 competed?
The extent of competition for SPE2DR26FRRN8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award